Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejim.2021.12.026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[A CASE OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS WITH RHINOSINUSITIS CONTROLLED WITH ENDOSCOPIC SINUS SURGERY].
Arerugi
December 2024
Department of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, The University of Tokyo.
Eosinophilic granulomatosis with polyangiitis (EGPA) is a disease with marked elevation of blood eosinophil associated with various symptoms in the respiratory tract, gastrointestinal tract, peripheral nerves, and skin due to systemic vasculitis. Here, we report a case of EGPA in which rhinosinusitis was treated with endoscopic sinus surgery (ESS) with good results. A 49-year-old man who developed bronchial asthma at age 48 was diagnosed with EGPA in our hospital.
View Article and Find Full Text PDFFactors influencing the prescription of add-on long-acting muscarinic antagonists in real-world asthma management: Insights from a national registry.
Respir Med
January 2025
Ankara University School of Medicine, Department of Chest Disease, Division of Immunology and Allergy, Ankara, Turkey.
Current guidelines recommend adding long-acting muscarinic antagonists (LAMAs) in patients with uncontrolled asthma, despite the use of moderate to high doses of inhaled steroid-long-acting beta agonists (ICS/LABA). This study aims to analyze the factors related to the prescription of add-on LAMA in clinical practice for asthma patients, shedding light on physicians' preferences. This study included adult asthma patients on add-on LAMA and ICS/LABA monitored for at least one year in a national registry comprising 2053 asthmatics.
View Article and Find Full Text PDFAchieving clinical remission in asthma with mepolizumab: a subanalysis on vitamin D as a predictor of response.
J Asthma
November 2024
Department of Pulmonology, Fortis Escorts Hospital, Faridabad, India.
Objective: Mepolizumab, an anti-IL-5 monoclonal antibody, has shown promise in reducing exacerbations and steroid dependency in severe eosinophilic asthma. This study aims to evaluate the effectiveness of mepolizumab in achieving clinical remission in asthma over 12 months and explore Vitamin D levels as a predictor of response.
Method: We assessed Asthma Control Questionnaire (ACQ) scores, spirometry, number of exacerbations, oral corticosteroid (OCS) use, and inhaled corticosteroid (ICS) use in 32 patients, observing significant clinical improvements.
Effects of Mepolizumab in the treatment of type 2 CRSwNP: a real-life clinical study.
Eur Arch Otorhinolaryngol
October 2024
Department of Otorhinolaryngology, Careggi University Hospital, Largo Brambilla, 3, Florence, 50134, Italy.
Purpose: Mepolizumab was recently approved for treating Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) unresponsive to standard treatment or recurring after endoscopic sinus surgery (ESS). To date, few studies have assessed Mepolizumab's efficacy in severe type-2 CRSwNP. Our study aimed to analyze sinonasal outcomes in type-2 CRSwNP patients treated with 100 mg Mepolizumab administered subcutaneously every four weeks.
View Article and Find Full Text PDFTemporal variation in the effectiveness of biologics in asthma: Effect modification by changing patient characteristics.
Respir Med
November 2024
Division of Allergy and Clinical Immunology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA. Electronic address:
Background: The underlying population of patients selected for each respiratory monoclonal antibody might change as other biologics are approved.
Objective: To evaluate effect modification by calendar time of the effectiveness of each respiratory biologics in asthma.
Methods: The Effectiveness of Respiratory biologics in Asthma (ERA) is a retrospective cohort of severe asthma patients from the Mass General Brigham clinics between January 2013 and September 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!